Breaking News

AbbVie, Voyager Expand Parkinson’s Pact

Aims to develop and commercialize vectorized antibodies for Parkinson's that circumvent the blood-brain barrier

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie and Voyager Therapeutics, Inc. entered an exclusive, global strategic collaboration and option agreement to develop and commercialize vectorized antibodies directed at pathological species of alpha-synuclein for the potential treatment of Parkinson’s and other diseases characterized by the abnormal accumulation of misfolded alpha-synuclein protein.     Voyager’s vectorized antibody platform and approach aims to circumvent the blood-brain barrier by delivering, with a potenti...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters